Evidence map›Paper›PMID 24240292›Full record

ReviewCurrent opinion in pediatrics2013

The expanding spectrum of the autoimmune lymphoproliferative syndromes.

João Bosco Oliveira

Abstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Case Report:Frontiers in immunology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Warm antibody autoimmune hemolytic anemia.Hematology. American Society of Hematology. Education Program · 2016
    Review
  13. Article
  14. Article
  15. Syndrome-Associated Tumors by Organ System.Journal of pediatric genetics · 2016
    Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

João Bosco OliveiraInstituto de Medicina Integral Prof. Fernando Figueira - IMIP.
Instituto de Medicina Integral Professor Fernando Figueira · BR

Funding

Immune Evaluation in Patients with Autoimmune Lymphoproliferative SyndromeZIACL010287 · CLC · CLINICAL CENTER · PI FLEISHER, THOMAS A · 2009 to 2015
$0k
Intramural NIH HHS ZIA CL010287
6 · The paper itself

Abstract

purpose of reviewSeveral autoimmune lymphoproliferative syndromes have been described lately. We review here the main clinical and laboratory findings of these new disorders. RECENT

findingsThe prototypical autoimmune lymphoproliferative syndrome (ALPS) has had its diagnostic criteria modified, somatic mutations in RAS genes were found to cause an ALPS-like syndrome in humans, and mutations in a gene encoding a protein kinase C (PRKCD) were discovered to cause a syndrome of lymphoproliferation, autoimmunity and natural killer cell defect. SUMMARY: The recent discoveries shed light on the molecular pathways governing lymphocyte death, proliferation and immune tolerance in humans.

Indexed as

Genes, rasApoptosisAutoimmune Lymphoproliferative SyndromeAutoimmunityCell ProliferationFas-Associated Death Domain ProteinFemaleHumansImmune ToleranceInflammationMaleMutationProtein Kinase C-deltaSignal TransductionFADD protein, humanFas-Associated Death Domain ProteinPRKCD protein, humanProtein Kinase C-delta

Identifiers

PMID24240292
PMCPMC4435794
OpenAlexW2086614915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.